KG-1Homo sapiens (Human)Cancer cell line

Also known as: KG1

🤖 AI SummaryBased on 13 publications

Quick Overview

Human leukemia cell line with JAK2 V617F mutation, used in myeloproliferative disorder research.

Detailed Summary

KG-1 is a human leukemia cell line derived from a patient with erythroleukemia that progressed to acute myeloid leukemia (AML). It is characterized by the presence of the JAK2 V617F mutation, which is commonly associated with myeloproliferative disorders (MPDs). This cell line is widely used in research to study the molecular mechanisms of MPDs and the role of JAK2 mutations in leukemogenesis. KG-1 has been utilized in studies investigating the effects of JAK2 inhibition and the genetic alterations associated with MPDs. Additionally, it has been part of comprehensive genomic and transcriptomic analyses to identify key mutations and expression patterns relevant to cancer research.

Research Applications

Myeloproliferative disorder researchJAK2 mutation studiesLeukemogenesis mechanismsDrug sensitivity testing

Key Characteristics

JAK2 V617F mutationAcute myeloid leukemia origin
Generated on 6/15/2025

Basic Information

Database IDCVCL_0374
SpeciesHomo sapiens (Human)
Tissue SourceBone marrow[UBERON:UBERON_0002371]

Donor Information

Age59
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseAcute myeloid leukemia
LineageMyeloid
SubtypeAcute Myeloid Leukemia
OncoTree CodeAML

DepMap Information

Source TypeATCC
Source IDACH-000386_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.672+1G>AHomozygousSplice donor mutationUnknown, Unknown, PubMed=1311061
MutationSimpleNRASp.Gly12Asp (c.35G>A)UnspecifiedSomaticWistar
Gene fusionFGFR1FGFR1OP2-FGFR1--from parent cell line KG-1

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
7
D13S317
11,12
D16S539
10,11
D18S51
10,18
D19S433
11,16.2
D21S11
28,29
D2S1338
20,23
D3S1358
15,16
D5S818
13
D7S820
8,10
D8S1179
13,14
FGA
22
Penta D
8,9
Penta E
7,13
TH01
7,8
TPOX
7,9
vWA
14,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.

Haferlach T., Shirahige K., Miyano S., Ogawa S.

Nat. Genet. 45:1232-1237(2013).

The importance of molecular cytogenetic analysis prior to using cell lines in research: the case of the KG-1a leukemia cell line.

Pelliccia F., Ubertini V., Bosco N.

Oncol. Lett. 4:237-240(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Biologicals 35:195-202(2007).

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.

Tsuchida M., Sugita K., Ida K., Hayashi Y.

Blood 103:1085-1088(2004).

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 25:275-278(2001).

Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.

Gaulton G.N., Ratajczak M.Z.

Leukemia 14:1821-1832(2000).

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 24:255-262(2000).

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Hirai H.

Jpn. J. Cancer Res. 89:33-39(1998).

Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia.

Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y.

Leuk. Res. 21:697-701(1997).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.

Imaizumi M., Endo M., Takano N., Konno T.

Leukemia 10:102-105(1996).

Human myeloid leukemia cell lines: a review.";

Koeffler H.P., Golde D.W.

Blood 56:344-350(1980).

Differential expression of the amv gene in human hematopoietic cells.

Aaronson S.A., Wong-Staal F.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:537-548(1985).

Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.

Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985).

Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:549-559(1985).

Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines.";

Jacob M.C., van den Elsen P., Terhorst C.P., Greaves M.F.

Blood 68:1101-1107(1986).

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:209-229(1985).

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Nakano A., Harada T., Morikawa S., Kato Y.

Acta Pathol. Jpn. 40:107-115(1990).

Frequent mutations in the p53 gene in human myeloid leukemia cell lines.

Ishikawa F., Takaku F., Yazaki Y., Hirai H.

Blood 79:2378-2383(1992).

Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity.

Koeffler H.P., Golde D.W.

Science 200:1153-1154(1978).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).